Claims

[Claim 1] A composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative having the amino acid sequence selected from the group consisting of SEQ ID NOs: 24-26 and 28.

[Claim 2] The composition according to claim 1, wherein the oxyntomodulin derivative is in the form of a conjugate linked to one selected from the group consisting of an immunoglobulin fragment, an antibody, elastin, albumin and fibronectin.

[Claim 3] The composition according to claim 2, wherein the conjugate is a conjugate in which the oxyntomodulin derivative whose amino acid sequence is selected from the group consisting of SEQ ID NOs: 24-26 and 28 is linked to an immunoglobulin Fc region via a non-peptidyl polymer.

[Claim 4] The composition according to claim 3, wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, an ethylene glycol/propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA (polylactic acid), PLGA (polylactic-glycolic acid), lipid polymers, chitin, hyaluronic acid, polysaccharide and combinations thereof.

[Claim 5] The composition according to claim 3, wherein one end of the non-peptidyl polymer and the other are linked to an amine group or a thiol group of the immunoglobulin Fc region and the oxyntomodulin derivative, respectively.

[Claim 6] The composition according to claim 1, further comprising a pharmaceutical agent showing preventive or therapeutic effects against hyperlipidemia, fatty liver disease or arteriosclerosis.

[Claim 7] The composition according to claim 1, wherein the fatty liver disease is non-alcoholic fatty liver disease, alcoholic fatty liver disease, nutritional fatty liver disease,

starvation fatty liver disease, obesity fatty liver disease, diabetic fatty liver disease, or steatohepatitis.

[Claim 8] The composition according to claim 7, wherein the non-alcoholic fatty liver disease results from hyperlipidemia, diabetes, or obesity.

[Claim 9] The composition according to claim 7, wherein the non-alcoholic fatty liver disease is selected from the group consisting of simple steatosis, non-alcoholic steatohepatitis, liver fibrosis and liver cirrhosis.